Современные аспекты и некоторые дискуссионные вопросы применения трастузумаба

1. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology. College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–45.
2. Jacobs TW, Gown AM, Yaziji H et al. Specificity of Hercep Test in determining HER-2/neu-status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983–7.
3. Hammond EH, Wolff AC, Hayes DF. Clinical notice for american society of clinical Oncology College of American Pathologists Guideline Recommendations on ER/PgR and HER-2-testing in breast cancer. J Clin Oncol 2011.
4. Ross JB. Breast cancer biomarkers and HER-2-testing after 10 years of anti-HER-2-therapy. Drug News Perspect 2009; 22 (2): 93–106.
5. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER-2-overexpressing breast cancer.  Ann Oncol 2007; 18 (6): 977–84.
6. Pietras RJ, Pegram MD, Finn RS et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2-receptor and DNA-reactive drugs. Oncogene 1998; 17: 2235–49.
7. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 2008; 9 (15): 2583–601.
8. Amar S, Moreno-Aspitia A, Perez EA. Issues and controversies in the treatment of HER-2-positive metastatic breast cancer. Breast Cancer Res Treat 2008; 109 (1): 1–7.
9. Dean-Colomb W, Esteva FJ. Her-2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008; 44 (18): 2806–12.
10. Dent S, Verma Sh, Latreille J et al. The role of her-2-targeted therapies in women with her-2-overexpressing metastatic breast cancer. Curr Oncol 2009; 16 (4): 25–35.
11. Minckwitz G, Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26 / breast international group 03–05 study. J Clin Oncol 2009; 27 (12): 1999–2006.
12. Sabnis GJ, Brodie AM. Trastuzumab improves the responsiveness of letrozole refractory human breast cells to endocrine therapy. Breast Cancer Res Treat 2006; 100 (Suppl. 1): 26.
13. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TANDEM study. J Clin Oncol 2009; 27 (33): 5529–37.
14. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28 (7): 1124–30.
15. Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced and recurrent. Curr Opin Obstet Gynecol 2011; 23 (1): 37–43.
16. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments for breast cancer: final results of the FinHER Trial. J Clin Oncol 2009; 27: 5685–92.
17. Perez EA, Suman VJ, Davidson NE et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER-2-positive adjuvant breast cancer trial. 32nd Annual San Antonio Breast Cancer Symposium 2009.  Abstr. 80.
18. Petrelli F, Barni S. Metaanalysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 2011.
19. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2/neu-positive early breast cancer patients: BCIRG 006 Study. 32nd Annual San Antonio Breast Cancer Symposium 2009. Abstr. 62.
20. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700–6.
21. NCCN Clinacal Practice Guidelines in Oncology. Breast Cancer 2010; http://www.nccn.org
22. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER-2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER-2-negative cohort. Lancet 2010; 375 (9712): 349–50.
23. Baselga J, Bradburry I, Eidtmann H et al. First results of the Neo ALTTO trial (BIG01-06/EGF106903): A phase III randomized open label neoadjuvant study of lapatinib, trastuzumab and their combination plus paclitaxel in women with HER-2-positive primary breast cancer. SABCS 2010. Abstr. 291.
24. Gianni L et al. Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study (NeoSphere). Cancer Res 2010; 70 (Suppl. 24): 3–12.
25. Dawood SS, Kristine B, Hortobagy GN et al. Prognosis of women with stage IV breast cancer by HER-2-status and trastuzumab treatment: an institutional based review. Proc ASCO 2008; 26 (15).  Abstr. 1018.

М.А.Фролова, М.Б.Стенина

НИИ клинической онкологии ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

________________________________________________

M.A.Frolova, M.B.Stenina

Research Institute of Clinical Oncology, N.N.Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow